Close Menu

NEW YORK (GenomeWeb) – Veracyte reported after the close of the market on Wednesday that its first quarter earnings rose 21 percent year over year.

For the three months ended March 31, the company reported revenues of $16.4 million, up from $13.6 million a year earlier, but missing the average analyst estimate for revenues of $17.7 million.

Veracyte said volume of its Afirma Gene Expression Classifier test rose 9 percent during Q1 to 5,834 tests.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.